Virtual Incision announced that it added a $30 million extension to its previous $46 million Series C financing round.
The funding will support regulatory and clinical programs leading to the commercialization of the MIRA, as well as for research and development efforts.
Virtual Incision said it has received an investigational device exemption for it Miniaturized In Vivo Robotic Assistant, or MIRA, platform for minimally invasive colon resection surgery.
Virtual Incision raised $20 million in a Series B financing round for its MIRA (miniaturized in vivo robotic assistant) surgical robotic platform. This brings the total financing for the Lincoln, Neb.-based company, which was founded in 2006, to $51 million. The company also filed for an FDA investigational device exemption for the MIRA platform so…
Virtual Incision has raised $10 million as it continues developing its miniaturized surgical robot.